Back to User profile » Dr Alfredo Maria Lurati
Papers published by Dr Alfredo Maria Lurati:
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Color duplex ultrasonography findings of temporal arteries in a case of giant cell arteritis: role in diagnosis and follow-up
Laria A, Lurati A, Scarpellini M
Open Access Rheumatology: Research and Reviews 2017, 9:55-59
Published Date: 15 March 2017
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
The macrophages in rheumatic diseases
Laria A, Lurati A, Marrazza M, Mazzocchi D, Re KA, Scarpellini M
Journal of Inflammation Research 2016, 9:1-11
Published Date: 9 February 2016
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Different T cells' distribution and activation degree of Th17 CD4+ cells in peripheral blood in patients with osteoarthritis, rheumatoid arthritis, and healthy donors: preliminary results of the MAGENTA CLICAO study
Lurati A, Laria A, Gatti A, Brando B, Scarpellini M
Open Access Rheumatology: Research and Reviews 2015, 7:63-68
Published Date: 16 October 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Calciphylaxis in a patient affected by rheumatoid arthritis, chronic renal failure, and hyperparathyroidism: a case report
![](cr_data/cache/submission_images/s80000/80441/07_jan_2015_figure_1_200_200_90.jpg)
Lurati A, Laria A, Paolotti D, Scarpellini M
International Medical Case Reports Journal 2015, 8:117-120
Published Date: 27 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
User preference for a portable syringe pump for iloprost infusion
![](cr_data/cache/submission_images/s81000/81473/31_mar_2015_figure_1_200_200_90.jpg)
Laria A, Lurati AM, Re KA, Marrazza MG, Mazzocchi D, Farina A, Scarpellini M
Patient Related Outcome Measures 2015, 6:139-144
Published Date: 19 May 2015
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab [Corrigendum]
Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M
Biologics: Targets and Therapy 2013, 7:265-266
Published Date: 6 December 2013
![Noteworthy comment: This study provides evidence that activation of natural killer cells can be used as an early predictor of response in patients with rheumatoid arthritis treated with rituximab. Activation of natural killer cells, measured 3 months after the first rituximab course, significantly correlated with clinical response at 6 months and 1 year, independently from other clinical variables. These results support the current scientific thought that natural killer cells may be effectors of antibody dependent cell mediated cytotoxicity induced by monoclonal antibody therapies, such as rituximab.](assets/img/article_icons/noteworthy.png)
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
NK cell count as predictor of clinical response in patients with rheumatoid arthritis treated with rituximab
Lurati A, Bertani L, Marrazza M, Re KA, Bompane D, Scarpellini M
Biologics: Targets and Therapy 2012, 6:83-87
Published Date: 11 April 2012
![Highly-accessed](assets/img/article_icons/highly-accessed.png)
Safety of etanercept in elderly subjects with rheumatoid arthritis
Alfredomaria Lurati, Mariagrazia Marrazza, Katia Angela, et al
Biologics: Targets and Therapy 2010, 4:1-4
Published Date: 22 December 2009